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ABSTRACT
Prostaglandin E2 (PGE2) contributes to tumor progression by promoting cancer 
cell growth, invasion and by creating a favorable pro-tumor microenvironment. PGE2 
has been reported to transactivate and internalize into the nucleus receptor tyrosine 
kinases such as Epidermal growth factor receptor (EGFR), thereby supporting tumor 
progression. Here we demonstrate that in non-small cell lung carcinoma (NSCLC) 
cells, PGE2 induces EGFR nuclear translocation via different dynamin-dependent 
endocytic pathways, promotes the formation of an EGFR-STAT3 complex, affects 
nuclear EGFR target gene expression and mediates tumor cell proliferation. Indeed, 
we find that PGE2 induces EGFR internalization and consequent nuclear import through 
Clathrin- and Caveolin-mediated endocytosis and through the interaction of EGFR 
with Importin β1. Within the nucleus, EGFR forms a complex with STAT3, an event 
blocked by ablation of Clathrin Heavy Chain or Caveolin-1. The combination of EGF and 
PGE2 prolongs nuclear EGFR transcriptional activity manifested by the upregulation 
of CCND1, PTGS2, MYC and NOS2 mRNA levels and potentiates nuclear EGFR-induced 
NSCLC cell proliferation. Additionally, NSCLC patients with high expression of a nuclear 
EGFR gene signature display shorter survival times than those with low expression, 
thus showing a putative correlation between nuclear EGFR and poor prognosis in 
NSCLC. Together, our findings indicate a complex mechanism underlying PGE2-induced 
EGF/EGFR signaling and transcriptional control, which plays a key role in cancer 
progression.
INTRODUCTION
Prostaglandin E2 (PGE2) promotes tumor growth by 
inducing an inflammatory microenvironment, in autocrine 
or paracrine fashion, through the activation of 4 receptor 
subtypes: EP1, EP2, EP3, EP4 [1–3]. Besides the plethora 
of biological processes evoked by prostanoids through the 
binding to their receptors, PGE2 reportedly interacts with 
various receptor tyrosine kinase (RTK) in a process termed 
transactivation [4], exemplified by EGFR activation 
in several cancer cell types [5–10]. Upon binding with 
PGE2, EP receptors trigger different downstream effectors 
including PKA, PKC, SRC and PI3K to mediate EGFR 
activation [11].
We have recently reported that PGE2 induces EGFR 
internalization and nuclear translocation supporting 
tumor progression in non-small cell lung cancer (NSCLC) 
cells [12]. Indeed, we have shown that PGE2-induced 
EGFR transactivation promotes its nuclear import and 
the subsequent SRC/ADAMs-mediated autocrine and/or 
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paracrine release of soluble cell-surface EGF like ligands, 
an event that culminates in EGFR-mediated transcriptional 
activities and enhanced tumor cell proliferation [12].
Numerous reports have shown that EGFR recruits 
proteins and transduces signaling pathways also 
inside the cell [13, 14]. Upon ligand binding, EGFR 
undergoes either Clathrin-mediated endocytosis (CME) 
or Clathrin-independent endocytosis (CIE), including 
lipid-raft dependent routes, such as Caveolin-mediated 
endocytosis and macropinocytosis [15]. EGFR is mainly 
internalized via Clathrin- mediated endocytosis [16], 
yet saturation of Clathrin or stimulation with different 
ligands has been shown to induce alternative routes of 
internalization, including Caveolin-mediated endocytosis 
and macropinocytosis [17–19].
In light of the above mentioned PGE2 -induced 
EGFR nuclear translocation, we have tested which 
internalization routes might be involved in EGFR 
nuclear shuttling in NSCLC cells and whether PGE2 
could sustain nuclear EGFR transcriptional activity and 
tumor progression. Here, we describe the internalization 
mechanisms by which PGE2 regulates EGFR nuclear 
translocation and affects tumor gene expression and cancer 
cell proliferation.
RESULTS
Inhibition of the large GTPase dynamin blocks 
PGE2-induced EGFR nuclear import
EGFR is internalized either via Clathrin-mediated 
endocytosis or via Caveolin-mediated endocytosis and 
macropinocytosis [16–18, 20]. In order to discriminate 
between the EGFR endocytic modalities induced by 
PGE2, we used pharmacological inhibitors of these 
pathways employing A549 and GLC82 NSCLC cells. 
Stimulation with either EGF (25 ng/ml) or PGE2 (1μM) 
induced EGFR nuclear translocation with a peak at 10 
and 60 min, respectively (Figure 1A and Supplementary 
Figure 1A). Clathrin- and Caveolin-mediated endocytosis 
are both dependent on the activity of the large guanosine 
5′-triphosphatase (GTPase) dynamin [21], whereas 
macropinocytosis is susceptible to Na+/H+ exchange 
inhibitors, such as amiloride [22]. Thus, A549 cells 
were pre-treated with a specific dynamin inhibitor, 
Dynasore (DYN), or with a Na+/H+ exchange inhibitor, 
5-(N-Ethyl-N-isopropyl) amiloride (EIPA) before 
challenge with EGF (Figure 1B) or PGE2 (Figure 1C). 
In EGF or PGE2-treated cells, DYN markedly reduced 
EGFR nuclear accumulation, whereas no effect was 
observed with EIPA (Figure 1B and 1C). Similar results 
were obtained with GLC82 cells (Supplementary Figure 
1B). Immunofluorescence staining followed by confocal 
microscopy analysis showed that in control conditions and 
in NSCLC cells treated with DYN or EIPA alone, EGFR 
was confined to the cell membrane (Figure 1D). DYN 
pretreatment of NSCLC cells blocked the nuclear import 
of EGFR induced by either EGF (10 min) or PGE2 (60 
min), whereas EIPA treatment failed to affect the EGFR 
internalization and nuclear translocation process (Figure 
1D). The results indicate that dynamin-dependent Clathrin- 
and Caveolin-mediated endocytosis might be involved in 
EGF and PGE2-induced EGFR nuclear translocation.
PGE2 promotes EGFR internalization and 
nuclear translocation via Clathrin- and 
Caveolin-mediated endocytosis
To further dissect the endocytic mechanism, we 
used a genetic approach to inhibit Clathrin and Caveolin-
mediated endocytosis by performing knockdown of both 
Clathrin Heavy Chain, the major component of Clathrin-
coated vesicles [23] and knockdown of Caveolin-1, the 
primary constituent of Caveolae [24]. A549 and GLC82 
cells were transiently transfected with siRNA against 
Clathrin Heavy Chain (siClathrin) or against Caveolin-1 
(siCaveolin-1) or with a non-targeting siRNA (siControl) 
for 48 hours and then treated with EGF (10 min) or 
PGE2 (60 min). Clathrin knockdown abrogated EGFR 
nuclear translocation induced by both EGF and PGE2, 
while Caveolin-1 ablation suppressed only PGE2-induced 
EGFR nuclear translocation (Figure 2A). The efficient 
knockdown of Clathrin Heavy chain and Caveolin-1 
expression was confirmed by immunoblotting (Figure 
2B). A similar phenotype was observed in GLC82 cells. 
Clathrin Heavy chain knockdown hindered both EGF and 
PGE2-mediated EGFR nuclear translocation. Conversely, 
knockdown of Caveolin-1 impaired only PGE2-mediated 
EGFR nuclear accumulation (Supplementary Figure 2A 
and 2B). Immunofluorescence confocal microscopy 
analysis confirmed the strong reduction of EGFR 
internalization and nuclear translocation in Clathrin Heavy 
chain knockdown setting (Figure 2C middle panels) and 
the dependency on Caveolin-mediated endocytosis of 
PGE2-induced EGFR nuclear translocation (Figure 2C 
lower panels). Knockdown of both Clathrin Heavy chain 
and Caveolin-1, impaired PGE2 activity to a similar 
extent as si-Clathrin Heavy chain or si-Caveolin-1 
alone, suggesting that the prostanoid appears to promote 
nuclear EGFR translocation with two independent 
signaling pathways (Supplementary Figure 3A). The 
efficient knockdown of Clathrin Heavy chain and 
Caveolin-1 expression was confirmed by immunoblotting 
(Supplementary Figure 3B).
To validate the results on Caveolin-mediated 
endocytosis, we employed Methyl-l β-cyclodextrin 
(MβCD), a cyclic oligomer of glucopyranoside that 
inhibits cholesterol-dependent Caveolae-mediated 
endocytosis, by reversibly extracting the steroid out of 
lipid rafts [25]. In A549 cells, incubated with increasing 
concentration of MβCD (1, 5, 10 mM) before EGF or 
PGE2 treatment, we found no effect on EGF-mediated 
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EGFR nuclear translocation (Figure 2D), whereas a 
reduced EGFR nuclear accumulation was observed after 
PGE2 stimulation, demonstrating that Caveolin-mediated 
endocytosis plays a role in PGE2-induced EGFR nuclear 
translocation (Figure 2E). Taken together, these findings 
underline the prominent role of Clathrin-mediated 
endocytosis in EGFR internalization, yet the data also 
demonstrates that Caveolin-mediated endocytosis is an 
alternative endocytic route for PGE2-induced nuclear 
translocation of EGFR.
Figure 1: Dynamin inhibition blocks EGF- and PGE2-induced EGFR nuclear translocation. Immunoblotting analysis of 
EGFR expression in cytosolic and nuclear fraction in overnight starved A549 (A–C). Cells were exposed to 10 min to 25ng/ml EGF or to 
60 min 1μM PGE2 (A). A549 cells were starved overnight and then treated for 30 min with dynasore 80μM (DYN) or 100μM 5-(N-Ethyl-N- 
isopropyl)amiloride (EIPA) before challenge with 25ng/ml EGF or 1μM PGE2 for 10 and 60 min respectively (B, C). Tubulin and Lamin A 
were used as loading control for cytosolic and nuclear fraction. Immunoblotting quantification was expressed in A.D.U. (arbitrary density 
unit) and as mean ± SD. *p < 0.05, **p < 0.01vs Ctrl. EGFR in the cytoplasmic and nuclear fractions was normalized to Tubulin or Lamin 
A respectively. (D) Confocal analysis of EGFR localization in A549 treated as described above and then fixed with paraformaldehyde and 
stained with anti-EGFR (green) and Propidium Iodide (red). Confocal images were captured in the middle section of the nuclei with Zeiss 
LSM700 microscope using 63x objective, scale bars 20 μm. The experiments were performed three times.
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Importin β1 is essential for PGE2-mediated 
EGFR nuclear translocation
Transport of proteins into the nucleus through 
the nuclear pore complex involves Importin α/β, which 
bind to nuclear localization signals in cargo substrates to 
promote nuclear entry [26]. Indeed, a putative tripartite 
NLS is present within the juxtamembrane domain of 
EGFR and is required for its nuclear import via association 
with Importin β1 [27, 28]. To assess whether Importin 
β1 was essential for PGE2-mediated EGFR nuclear 
translocation, as demonstrated for EGF, we performed 
Figure 2: PGE2 promotes EGFR internalization via Clathrin- and Caveolin-mediated endocytosis. (A) A549 cells were 
transfected with siRNA control or siRNAs against Clathrin Heavy Chain or Caveolin-1 for 24 h. Cells were then serum starved overnight 
and then exposed to 25ng/ml EGF for 10 min or to 1μM PGE2 for 60 min. EGFR level in cytoplasmic and nuclear fraction was assessed 
using immunoblot with indicated antibodies. Tubulin and Lamin A were used as loading control for cytosolic and nuclear fraction. (B) 
Knockdown efficiency was verified by immunoblotting with Clathrin Heavy Chain or Caveolin-1 antibodies, actin was used as loading 
control. Data are shown only for siClathrin-A and siCaveolin-1A, similar data were obtained with siClathrin-B and siCaveolin-1B. (C) 48 
h post transfection, cells were treated with EGF or PGE2 as indicated in the panels, fixed and stained for EGFR (green) and DAPI (blue). 
Pictures were acquired in the middle section of nuclei at 63x magnification. Scale bars, 20μm. Panel shows representative picture for 
each experimental condition. Boxed areas are shown in detail in the inset. (D-E) A549 cells were starved overnight and then treated with 
Metil β-cyclodextrin (MβCD) 1, 5 and 10 mM for 30 min before challenge with 25ng/ml EGF (D) or 1μM PGE2 (E) for 10 and 60 min 
respectively. Immunoblotting analysis on cytoplasmic and nuclear fractions was then performed with indicated antibodies. Immunoblotting 
quantification was expressed in A.D.U. (arbitrary density unit) and as mean ± SD. *p < 0.05, **p < 0.01 vs Ctrl. EGFR in the cytoplasmic 
and nuclear fractions was normalized to Tubulin or Lamin A respectively. The experiments were performed three times.
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a knockdown of Importin β1 by transfecting A549 cells 
with siRNA against Importin β1 or with a non-targeting 
siRNA (siControl). Exposure to EGF or PGE2 of Importin 
β1-silenced cells dramatically reduced EGFR nuclear 
translocation upon both EGF and PGE2 treatments (Figure 
3A). Downregulation of Importin β1 was assessed by 
immunoblotting analysis (Figure 3B). The role of Importin 
β1 was further validated by immunofluorescence confocal 
microscopy analysis. In Importin β1-ablated cells, EGFR 
was still mobilized from cell membrane upon both EGF 
and PGE2 treatment, however, nuclear localization was 
abrogated (Figure 3C). These results demonstrate that, 
as for EGF, PGE2-mediated EGFR nuclear translocation 
requires Importin β1.
PGE2 induces the formation of an EGFR-STAT3 
complex in the nucleus
As EGFR lacks a DNA binding domain, nuclear 
EGFR exerts its transcriptional functions via the 
interaction with various transcription factors [29]. Among 
the transcriptional target genes, nuclear EGFR is recruited 
to the ATRS motif of the cyclin D1 (CCND1), inducible 
nitric oxide synthase (NOS2), c-Myc (MYC) and COX-
2 (PTGS2) promoters through its interaction with several 
transcription factors, including STAT3 [30–34]. We 
previously observed that CCND1, PTGS2, MYC and 
NOS2 were highly modulated by PGE2-induced nuclear 
EGFR [12]. Thus, we first investigated whether PGE2 
promoted STAT3 phosphorylation and then the role of 
JAK in mediating this signaling pathway. In A549 cells 
exposed to PGE2 from 5 to 60 min, the prostanoid induced 
STAT3 activation in a time-dependent manner with a peak 
at 30 min (Figure 4A). Next, 30 minutes pre-treatment of 
NSCLC cells with a JAK inhibitor, Ruxolitinib at 10μM, 
as well as with a STAT3 inhibitor, STAT3 inhibitor VII at 
10μM, significantly reduced the PGE2 effect (Figure 4B).
Notably, PGE2 promoted EGFR-STAT3 
protein–protein interaction as determined by co-
immunoprecipitation experiments. A549 cells were 
exposed to EGF (10 min) or PGE2 (60 min), and EGFR 
was immunoprecipitated and the potential binding of 
STAT3 to EGFR was analyzed by immunoblotting. 
Upon EGF and PGE2 treatment, STAT3, either in its non-
phosphorylated or phosphorylated condition, efficiently 
co-immunoprecipitated with EGFR (Figure 4C, 4D). In 
order to show whether EGFR and STAT3 form a complex 
inside the nucleus, we performed cell fractionation 
followed by immunoprecipitation. We observed that 
EGFR was bound to STAT3 in the nucleus suggesting a 
possible mechanism for the transcriptional activation of 
the PTGS2, MYC and NOS2 genes (Figure 4E). To assess 
the contribution of the two above-described internalization 
routes on EGFR transcriptional activity, we transiently 
transfected A549 and GLC82 cells with siRNAs against 
Clathrin Heavy Chain (siClathrin) or against Caveolin-1 
(siCaveolin-1) or with a non-targeting siRNA (siControl) 
for 48 hours before treatment with EGF (10 min) or 
PGE2 (60 min) (Figure 4F and Supplementary Figure 
4A). In Clathrin-ablated A549 cells exposed to EGF or 
PGE2, the formation of an EGFR-STAT3 complex was 
significantly reduced, confirming the central role of 
Clathrin-mediated endocytosis in EGFR internalization 
(Figure 4F and Supplementary Figure 4A middle panels). 
However, Caveolin-1 silencing affected PGE2-induced 
EGFR-STAT3 association, corroborating the ability of 
the prostanoid to use an alternative endocytic pathway 
(Figure 4F and Supplementary Figure 4A right panels). 
The knockdown efficiency of Clathrin Heavy chain and 
Caveolin-1 was confirmed by immunoblotting analysis 
blot (Figure 4G and Supplementary Figure 4B). The 
simultaneous knockdown of both Clathrin Heavy chain 
and Caveolin-1 did not appear to modify PGE2 efficacy 
on EGFR-STAT3 nuclear association, compared to 
knockdown of Clathrin Heavy chain or Caveolin-1 alone 
(Supplementary Figure 5A). The knockdown efficiency of 
Clathrin Heavy chain and Caveolin-1 was confirmed by 
immunoblotting analysis blot (Supplementary Figure 5B). 
Taken together, our data demonstrate that PGE2 induces 
the formation of an EGFR-STAT3 nuclear complex and 
that different endocytic mechanisms contribute to the 
association of EGFR with STAT3.
Combination of EGF and PGE2 promotes the 
transcription of nuclear EGFR target genes up 
to 8 hours
We previously reported that EGF and PGE2 alone 
induced the transcription of the nuclear EGFR-target 
genes CCND1, PTGS2, MYC and NOS2, with a maximal 
activation at 2 h and 4 h, respectively [12]. To assess 
the effect of a combination of EGF and PGE2 on the 
expression of these nuclear EGFR transcriptional target 
genes, A549 EGFR-knockout cells were generated by 
CRISPR/Cas9 (Figure 5A). Two cell clones, genetically 
deficient for EGFR expression (EGFR −/− #1 and #2), 
were transfected with plasmid constructs either encoding 
for wild type EGFR (WT) or EGFR mutated in its 
nuclear localization sequence (NLSm12 and dNLS) 
[32]. In NSCLC cells transfected with NLSm12 or dNLS 
constructs, EGFR nuclear translocation, promoted by 
the challenge with EGF or PGE2, was markedly reduced 
compared to cells transfected with WT EGFR or to 
parental cells (Figure 5B, 5C) [12].
A549 cells transfected with constructs encoding 
for WT and mutant EGFR showed similar level of 
EGFR expression (Figure 5D). Quantitative real-time 
PCR (qRT-PCR) analysis was performed in parental and 
modified A549 cells (Figure 6) exposed to EGF or PGE2 
or a combination in a time course up to 12 or 18 hours. 
In parental and EGFR -/- A549 cells bearing EGFR WT 
plasmid, EGF promoted the expression of nuclear EGFR 
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Figure 3: Importin β1 is required for EGFR nuclear translocation. (A) A549 cells were transfected with siRNA control or 
siRNA against Importin β1 for 48h. Next, cells were serum starved overnight and exposed to 25ng/ml EGF for 10 min or to 1μM PGE2 
for 60 min. EGFR level in cytoplasmic and nuclear fraction was assessed using immunoblot with indicated antibodies. (B) Knockdown 
efficiency was verified via western blot with Importin β1 antibody, Tubulin was used as loading control. Similar data were obtained with 
siImportin β1-B. Immunoblotting quantification was expressed in A.D.U. (arbitrary density unit) and as mean ± SD. *p < 0.05, **p < 0.01 vs 
Ctrl. EGFR in the cytoplasmic and nuclear fractions was normalized to Tubulin or Lamin A respectively. (C) A549 cells were transfected 
as indicated above. After that cells were fixed and stained for EGFR (green) and DAPI (blue). Confocal images were captured in the 
middle section of the nuclei with Leica SP5 confocal using 63x objective, scale bars 20 μm. Panel shows representative picture for each 
experimental condition. Boxed areas are shown in detail in the inset. The experiments were performed three times.
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target genes with a peak at 2 h and declined to baseline 
at 4-8 h, whereas PGE2 mimicked the EGF effect on 
target genes with a peak at 4 h and declined toward the 
baseline at 8-12 h. The combination of EGF and PGE2 
recapitulated the outcome of both individual treatments, 
yet showing a fostered transcription of target genes up to 
8 h (Figure 6). Similar results were observed in GLC82 
cells (Supplementary Figure 6). The statistical analysis is 
presented in Tables 1–2 and Supplementary Table 1 for 
A549 and GLC82 cells, respectively.
Next, we investigated the prognostic role of the 
nuclear EGFR gene signature. We exploited the Lung 
Figure 4: PGE2 induces the formation of EGFR-STAT3 complex into the nucleus. (A) Immunoblotting analysis of STAT3 
phosphorylation on Tyr 705 in overnight starved A549 exposed to 1 μM PGE2 for 5–60 min. (B) Immunoblotting analysis of STAT3 
phosphorylation on Tyr 705 in A549 exposed for 30 min to 1 μM PGE2, with or without pre-incubation with JAK inhibitor, Ruxolitinib (10 
μM), or STAT3 inhibitor, STAT3 inhibitor VII, for 30 min. Actin was used as loading control. (C–E) A549 cells were overnight starved 
and then exposed to 25ng/ml EGF or 1μM PGE2 for 10 and 60 min respectively. Whole cell lysate (C-D) and nuclear extract (E) were 
subjected to immunoprecipitation with anti-EGFR antibody and analyzed by immunoblotting with anti-STAT3 or anti-phosphoSTAT3 Try 
705 antibodies. (F) A549 cells were transfected with siRNA Control or siRNA against Clathrin Heavy Chain or against Caveolin-1 for 24 
h. Cells were then serum starved overnight and treated with 25ng/ml EGF for 10 min or 1μM PGE2 for 60 min. Whole cell lysates were 
subjected to immunoprecipitation with anti-EGFR antibody and analyzed by immunoblotting with anti-STAT3 antibody. (G) Knockdown 
efficiency was verified via western blot with Clathrin heavy chain and Caveolin-1 antibodies, actin was used as loading control. Data 
are shown only for siClathrin-A and siCaveolin-1A, similar data were obtained with siClathrin-B and siCaveolin-1B. Immunoblotting 
quantification was expressed in A.D.U. (arbitrary density unit) and as mean ± SD. *p < 0.05, **p < 0.01 vs Ctrl. In panel A and B, pSTAT3 
Tyr 705 was normalized to STAT3. In panels C-F, STAT3 was normalized to EGFR. The experiments were performed three times.
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Adenocarcioma TCGA study, including 230 tumor 
samples with mRNA expression data (RNA Seq V2) 
by cBioPortal for Cancer Genomics data sets [35, 36]. 
Alterations, which consists in mRNA upregulation of 
the nuclear EGFR target genes were found in 51 of 230 
patients (22%) as shown in percentages of total samples 
as follows: CCND1 (10%), PTGS2 (3%), MYC (8%) 
and NOS2 (1,7%) (Figure 7). Kaplan–Meier analysis for 
predicted overall patient survival indicated that cases with 
alteration of nuclear EGFR gene signature had shorter 
survival times than those with no alternation (log-Rank 
test, P < 0.0777), the median survival time being reduced 
from 46.7 to 35.5 months (Figure 7). Notably, in the 
group of patients with mRNA upregulation of nuclear 
EGFR target genes, the deceased patients were 16 on 44 
(36.3%), whereas in the group of patients without mRNA 
upregulation of nuclear EGFR target genes the deceased 
ones were 47 on 159 (29.5%). These data indicate a trend, 
Figure 5: Generation and characterization of a model to study nuclear EGFR functions. (A) Immunoblotting analysis 
of EGFR expression in A549 wild type cells and two clones knockout for EGFR, generated by CRISPR/Cas9 (EGFR -/- #1, #2). Actin 
was used as loading control. (B–C) EGFR knockout cells were transiently transfected with Vector or EGFR-WT or EGFR NLS mutant 
(NLSm12 or dNLS) plasmids for 48 h. Then EGFR nuclear import in response to 25 ng/ml EGF for 10 min (B) or to 1 μM PGE2 for 60 min 
(C) was analyzed by immunoblotting upon cell fractionation. Parental cells were included as a control. Tubulin and Lamin A were used as 
loading control for cytosolic and nuclear fraction respectively. Immunoblotting quantification was expressed in A.D.U. (arbitrary density 
unit) and as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 vs Ctrl. EGFR in the cytoplasmic and nuclear fractions was normalized to Tubulin 
or Lamin A respectively. (D) Expression of EGFR in EGFR -/- #1 cells, transfected with Vector, EGFR-WT and NLS mutant plasmids for 
96 h. Actin was used as loading control. The experiments were performed three times.
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Figure 6: The combination of EGF and PGE2 induces the transcription of nuclear EGFR gene signature up to 8 hours. 
Parental and modified A549 cells were starved overnight and then treated with 25 ng/ml EGF or 1 μM PGE2 or the combination for 2, 4, 
8, 12, or 18 h. RNA was isolated and analyzed by qRT-PCR for a panel of nuclear EGFR target genes. The data are presented as mean of 
fold change ± SD of three independent experiments, relative to non-treated cells (Control), which were assigned to 1. Statistical analysis is 
reported in Table 1 and Table 2. The experiments were performed three times.
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even not statistically significant, between nuclear EGFR 
activity and poor prognosis in lung adenocarcinoma 
patients.
EGF and PGE2 combination promotes NSCLC 
cell proliferation
To investigate whether the transcription of nuclear 
EGFR target genes-induced by the combination of 
EGF and PGE2 could mediate and sustain NSCLC cell 
proliferation compared to single stimuli, the A549 EGFR-
knockout cells described above were used. GLC82 cells 
knockout for EGFR were generated accordingly and 
transfected with Empty Vector, or EGFR WT, or NLS 
mutant plasmids (Supplementary Figure 7A-7B). Similar 
level of EGFR expression was observed in A549 and 
GLC82 cells transfected with constructs encoding for WT 
and mutant (Figure 8A and Supplementary Figure 7C).
Specifically, we assessed whether the disruption of 
nuclear import of EGFR affected cancer cell proliferation. 
NSCLC cell proliferation was quantified by using a 
5-bromo-2′-deoxy-uridine (BrdU) incorporation assay 
for 8-48 h (Figure 8B–8F and Supplementary Figure 7D-
7H). In parental and EGFR WT expressing A549 cells, 
EGF and PGE2 alone induced cell proliferation in a time-
dependent manner with a peak at 16 h, declining toward 
Table 1: Statistical analysis of nuclear EGFR target genes regulated by EGF and PGE2 in parental A549 cells
CCND1
2h 4h 8h 12h 18h
EGF vs Ctrl 0.0202 (*) 0.0479 (*) 0.9818 (ns) 0.1253 (ns) 0.2311 (ns)
PGE2 vs Ctrl 0.2561 (ns) 0.0422 (*) 0.1211 (ns) 0.9392 (ns) 0.6259 (ns)
EGF+PGE2 vs Ctrl 0.0447 (*) 0.0353 (*) 0.0493 (*) 0.2988 (ns) 0.101 (ns)
EGF+PGE2 vs EGF 0.731 (ns) 0.1028 (ns) 0.0924 (ns) 0.0983 (ns) 0.0795 (ns)
EGF+PGE2 vs PGE2 0.1013 (ns) 0.6912 (ns) 0.2138 (ns) 0.2659 (ns) 0.1448 (ns)
PTGS2
2h 4h 8h 12h 18h
EGF vs Ctrl 0.0197 (*) 0.2288 (ns) 0.7446 (ns) 0.5062 (ns) 0.9311 (ns)
PGE2 vs Ctrl 0.7688 (ns) 0.028 (*) 0.0205 (*) 0.1481 (ns) 0.1884 (ns)
EGF+PGE2 vs Ctrl 0.009 (**) 0.0013 (**) 0.0366 (*) 0.035 (*) 0.6021 (ns)
EGF+PGE2 vs EGF 0.2117 (ns) 0.1286 (ns) 0.0881(ns) 0.045 (*) 0.7091 (ns)
EGF+PGE2 vs PGE2 0.0168 (*) 0.9534 (ns) 0.6262 (ns) 0.1562 (ns) 0.3235 (ns)
MYC
2h 4h 8h 12h 18h
EGF vs Ctrl 0.0441 (*) 0.4918 (ns) 0.4346 (ns) 0.3573 (ns) 0.2127 (ns)
PGE2 vs Ctrl 0.6387 (ns) 0.0181 (*) 0.0648 (ns) 0.1924 (ns) 0.182 (ns)
EGF+PGE2 vs Ctrl 0.0099 (**) 0.0478 (*) 0.0053 (**) 0.0038 (**) 0.2197 (ns)
EGF+PGE2 vs EGF 0.9568 (ns) 0.1388 (ns) 0.02 (*) 0.1441 (ns) 0.5973 (ns)
EGF+PGE2 vs PGE2 0.0112 (*) 0.296 (ns) 0.0058 (**) 0.1791 (ns) 0.8109 (ns)
NOS2
2h 4h 8h 12h 18h
EGF vs Ctrl 0.0448 (*) 0.2372 (ns) 0.6838 (ns) 0.4729 (ns) 0.1667 (ns)
PGE2 vs Ctrl 0.8677 (ns) 0.0208 (*) 0.1401 (ns) 0.265 (ns) 0.5583 (ns)
EGF+PGE2 vs Ctrl 0.0478 (*) 0.0184 (*) 0.0096 (**) 0.1155 (ns) 0.0421 (*)
EGF+PGE2 vs EGF 0.457 (ns) 0.0196 (*) 0.0337 (*) 0.1283 (ns) 0.0354 (*)
EGF+PGE2 vs PGE2 0.0982 (ns) 0.3008 (ns) 0.1936 (ns) 0.7193 (ns) 0.0835 (ns)
ns = non significant; * p < 0.05; ** p < 0.01.
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baseline at 36–48h. In cells exposed to a combination 
of EGF and PGE2, BrdU incorporation levels increased 
at 16 h, doubled at 24 h and declined to baseline at 48 
h, indicating that EGF and PGE2 combination-induced 
nuclear EGFR sustained NSCLC cells growth (Figure 
8B–8F). In contrast, cells expressing EGFR-NLS mutants 
were not comparably stimulated to proliferate in response 
to neither EGF nor PGE2 (Figure 8B–8F). Similar results 
were obtained in GLC82 cells (Supplementary Figure 7D-
7H). Statistical analysis has been reported in Table 3 and 
Supplementary Table 2 for A549 and GLC82 respectively.
In summary, we have identified the mechanisms 
by which PGE2 promotes EGFR nuclear translocation in 
human NSCLC cells. PGE2 internalizes EGFR through 
Clathrin and Caveolin- mediated endocytosis, whereas 
EGF preferentially promotes Clathrin-mediated EGFR 
internalization. Inside the cell, EGFR is imported to the 
nucleus by Importin β1 and associates with activated 
STAT3, and potentially other transcription factors, to 
induce the expression of nuclear EGFR target genes, 
thereby promoting cancer cell proliferation (Figure 9). 
The gene signature linked to EGFR nuclear internalization 
Table 2: Statistical analysis of nuclear EGFR target genes regulated by EGF and PGE2 in EGFR knockout A549 cells 
bearing EGFR WT
CCND1
2h 4h 8h 12h
EGF vs Ctrl 0.0144(*) 0.0369(*) 0.7879(ns) 0.1404(ns)
PGE2 vs Ctrl 0.5417(ns) 0.0228(*) 0.2119(ns) 0.3722(ns)
EGF+PGE2 vs Ctrl 0.0220(*) 0.0247(*) 0.0236(*) 0.3111(ns)
EGF+PGE2 vs EGF 0.3542(ns) 0.2529(ns) 0.0368(*) 0.6618(ns)
EGF+PGE2 vs PGE2 0.0470(*) 0.6414(ns) 0.0497(*) 0.8610(ns)
PTGS2
2h 4h 8h 12h
EGF vs Ctrl 0.0162(*) 0.0824(ns) 0.9108(ns) 0.2415(ns)
PGE2 vs Ctrl 0.9602(ns) 0.0135(*) 0.0432(*) 0.2181(ns)
EGF+PGE2 vs Ctrl 0.0043(**) 0.0188(*) 0.0179(*) 0.2992(ns)
EGF+PGE2 vs EGF 0.3345(ns) 0.2700(ns) 0.0387(*) 0.9850(ns)
EGF+PGE2 vs PGE2 0.0150(*) 0.4289(ns) 0.0632(ns) 0.9204(*)
MYC
2h 4h 8h 12h
EGF vs Ctrl 0.0084(**) 0.0593(ns) 0.1278(ns) 0.4770(ns)
PGE2 vs Ctrl 0.0169(*) 0.0097(**) 0.1092(ns) 0.7608(ns)
EGF+PGE2 vs Ctrl 0.0156(*) 0.0042(**) 0.025(*) 0.2060(ns)
EGF+PGE2 vs EGF 0.4077(ns) 0.0194(*) 0.0485(*) 0.6039(ns)
EGF+PGE2 vs PGE2 0.1783(ns) 0.7295(ns) 0.0761(ns) 0.2999(ns)
NOS2
2h 4h 8h 12h
EGF vs Ctrl 0.0222(*) 0.1138(ns) 0.4012(ns) 0.4141(ns)
PGE2 vs Ctrl 0.4770(ns) 0.0043(**) 0.1694(ns) 0.3840(ns)
EGF+PGE2 vs Ctrl 0.0151(*) 0.0087(**) 0.0176(*) 0.1467(ns)
EGF+PGE2 vs EGF 0.1451(ns) 0.0534(ns) 0.0477(*) 0.1423(ns)
EGF+PGE2 vs PGE2 0.1716(ns) 0.9180(ns) 0.0452(*) 0.3600(ns)
ns = non significant; * p < 0.05; ** p < 0.01.
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in NSCLC cell lines matches that of patients with poor 
prognosis observed in patient with early stage NSCLC 
[37], suggesting a potential correlation with the clinical 
setting.
DISCUSSION
The inflammatory mediator PGE2 is known to favor 
growth of several epithelial tumor cells in which the 
oncogenic drive is sustained by EGF/EGFR system. Two 
mechanisms are recognized as inducers of EGFR-mediated 
oncogenicity. The first one, occurring predominately 
at the cell membrane, consists in the activation of the 
receptor followed by a well-known effector cascade 
[38]. The second one involves EGFR internalization 
from the plasma membrane to the nucleus in which it 
serves as co-transcriptional factor [29, 39]. Recently, 
we dissected the mechanisms of PGE2-mediated EGFR 
nuclear translocation showing marked differences in the 
kinetic and in the internalization pattern between EGF and 
PGE2 [12]. Here, we tested whether different endocytic 
mechanisms are involved in EGF and PGE2-mediated 
EGFR nuclear translocation. Based on differences in 
time of induction and the internalization patterns, we 
hypothesized distinct mechanisms promoted by EGF or 
PGE2.
EGFR is mainly internalized via Clathrin-mediated 
endocytosis [16] nevertheless, saturation of Clathrin or 
stimulation with different ligands could trigger alternative 
routes of internalization, including Caveolin-mediated 
endocytosis and macropinocytosis [17–19]. Using 
pharmacological inhibitors and siRNA targeting Clathrin 
heavy chain and Caveolin-1, we found that Clathrin 
knockdown abrogated EGFR nuclear translocation upon 
either EGF or PGE2 treatment. However, Caveolin-1 
knockdown or pharmacological inhibition (methyl-β-
cyclodextrin (MβCD) suppressed solely PGE2-mediated 
EGFR internalization (Figures 1–2, Supplementary 
Figure 7: Bioinformatics analysis of nuclear EGFR gene signature in NSCLC patients using cBioPortal database. 
Alterations in nuclear EGFR target genes across TGCA provisional Lung adenocarcinoma samples analyzed by cBioPortal for cancer 
genomics database. Data were filtered for mRNA upregulation of nuclear EGFR target genes and the percentage on total samples was 
reported. Overall Survival Kaplan–Meier Estimate curve in lung adenocarcinoma patients with alteration (n= 44) or without alteration 
(n=159) in nuclear EGFR gene signature (Logrank Test P-Value: 0.0777). The table below the graph summarizes the total cases, deceased 
cases and median months survival data.
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Figures 1–2). These findings demonstrate that Clathrin 
has a key role in EGFR internalization, whereas PGE2 
uses Caveolin as an alternative endocytic route to shuttle 
EGFR from the cell membrane to the nucleus. Notably, 
the uptake kinetics of Caveolin-mediated endocytosis is 
slower than that of Clathrin [40, 41], an observation that 
may explain the differences in the kinetics between EGF 
and PGE2-mediated EGFR nuclear import. Moreover, 
we do not observe any enhancement in the modulation 
of PGE2 activity on nuclear EGFR translocation when 
NSCLC cells were silenced for Clathrin heavy chain and 
Caveolin-1 together, suggesting that the two endocytic 
pathways activated by the prostanoid work independently 
(Supplementary Figure 3). However, we may not exclude 
that due to technical limitation, we could not discern the 
quantitative contribution of each individual endocytic 
routes.
As nuclear import of proteins bearing nuclear 
localization sequence (NLS) requires the interaction with 
Importin α/β for nuclear internalization [11], we show the 
key role of Importin β1 in PGE2-mediated EGFR nuclear 
translocation, as already reported for EGF (Figure 3).
Transcriptional regulation of genes involved in cell 
proliferation is one of the main functions of nuclear EGFR 
[39]. EGFR lacks a DNA binding domain and exerts its 
co-transcriptional functions via association with several 
transcription factors, including STAT3, STAT5 and E2F1 
[42]. Among nuclear EGFR target genes, previously 
shown to be modulated by PGE2 in NSCLC cells, PTGS2, 
MYC and NOS2 have been shown to be induced by the 
EGFR-STAT3 complex [12, 31, 32, 34].
Based on these notions, we investigated whether 
PGE2 leads to STAT3 activation and we found that the 
prostainoid promotes STAT3 phosphorylation with a peak 
Figure 8: EGF and PGE2 induce nuclear EGFR-mediated A549 cell proliferation. (A) Immunoblotting analysis of EGFR 
expression in A549 EGFR -/- #1 cells transfected with Vector, EGFR-WT and NLS mutant plasmids for 96 h. Parental cells were included 
as a control. Actin was used as loading control. (B–F) Parental cells or EGFR -/- #1, #2 cells transfected with Vector or EGFR WT or EGFR 
NLS12 or EGFR dNLS mutant plasmids for 24 h were harvested and seeded for BrdU incorporation assay. Cell proliferation was assessed 
by measuring the luminescence after 8, 16, 24, 36, 48 h treatment with EGF or PGE2 or the combination. Data are mean ± SD of triplicate 
cultures, expressed as % of control. Statistical analysis is reported in Table 3.
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at 30 min (Figure 4A). Upstream to STAT3 activation 
mediated by PGE2, JAK activity appears to be required, 
as its inhibition significantly reduced PGE2-mediated 
activity (Figure 4B). We have assessed a direct EGFR-
STAT3 interaction by co-immunoprecipation and find that 
STAT3, in both non-phosphorylated and phosphorylated 
Table 3: Statistical analysis of BrdU incorporation assay performed in A549
Parental Cells
8h 16h 24h 36h 48h
EGF vs Ctrl 0.6082 (ns) 0.0009 (***) 0.0007 (***) 0.0005 (***) 0.026 (*)
PGE2 vs Ctrl 0.0012 (***) 0.0004 (***) 0.0251 (*) 0.0187 (*) 0.9111 (ns)
EGF+PGE2 vs Ctrl 0.0399 (*) 0.0021 (**) 0.0002 (***) 0.0001 (***) 0.0627 (ns)
EGF+PGE2 vs EGF 0.1207 (ns) 0.0493 (*) 0.0146 (*) 0.1148 (ns) 0-9314 (ns)
EGF+PGE2 vs PGE2 0.5137 (ns) 0.208 (ns) 0.0163 (*) 0.044 (*) 0.1124 (ns)
Empty Vector
8h 16h 24h 36h 48h
EGF vs Ctrl 0.0503 (ns) 0.3501 (ns) 0.5735 (ns) 0.0701 (ns) 0.3463 (ns)
PGE2 vs Ctrl 0.5394 (ns) 0.2854 (ns) 0.1136 (ns) 0.5076 (ns) 0.108 (ns)
EGF+PGE2 vs Ctrl 0.2124 (ns) 0.774 (ns) 0.7895 (ns) 0.0678 (ns) 0.1904 (ns)
EGF+PGE2 vs EGF 0.244 (ns) 0.4509 (ns) 0.8338 (ns) 0.3226 (ns) 0.6124 (ns)
EGF+PGE2 vs PGE2 0.3548 (ns) 0.5563 (ns) 0.5839 (ns) 0.544 (ns) 0.9156 (ns)
EGFR WT
8h 16h 24h 36h 48h
EGF vs Ctrl 0.0469 (*) 0.004 (**) 0.0008 (***) 0.0073 (**) 0.4643 (ns)
PGE2 vs Ctrl 0.1155 (ns) 0.007 (**) 0.0003 (***) 0.0071 (**) 0.0334 (*)
EGF+PGE2 vs Ctrl 0.936 (ns) 0.0007 (***) 0.0002 (***) 0.0012 (**) 0.0073 (**)
EGF+PGE2 vs EGF 0.1425 (ns) 0.3505 (ns) 0.0116 (*) 0.0382 (*) 0.1133 (ns)
EGF+PGE2 vs PGE2 0.5206 (ns) 0.8089 (ns) 0.0024 (**) 0.0104 (*) 0.1261 (ns)
EGFR NLS12
8h 16h 24h 36h 48h
EGF vs Ctrl 0.1777 (ns) 0.0113 (*) 0.0121 (*) 0.0189 (*) 0.3301 (ns)
PGE2 vs Ctrl 0.9847 (ns) 0.0199 (*) 0.0183 (*) 0.0177 (*) 0.4278 (ns)
EGF+PGE2 vs Ctrl 0.1889 (ns) 0.1268 (ns) 0.0016 (**) 0.1341 (ns) 0.1984 (ns)
EGF+PGE2 vs EGF 0.0856 (ns) 0.5404 (ns) 0.1505 (ns) 0.0517 (ns) 0.1943 (ns)
EGF+PGE2 vs PGE2 0.363 (ns) 0.3641 (ns) 0.1791 (ns) 0.1107 (ns) 0.9641 (ns)
EGFR dNLS
8h 16h 24h 36h 48h
EGF vs Ctrl 0.6342 (ns) 0.1039 (ns) 0.0015 (**) 0.043 (*) 0.0232 (*)
PGE2 vs Ctrl 0.116 (ns) 0.0482 (*) 0.1585 (ns) 0.1676 (ns) 0.1562 (ns)
EGF+PGE2 vs Ctrl 0.0122 (*) 0.6773 (ns) 0.352 (ns) 0.4671 (ns) 0.1562 (ns)
EGF+PGE2 vs EGF 0.1783 (ns) 0.5399 (ns) 0.1325 (ns) 0.9016 (ns) 0.1454 (ns)
EGF+PGE2 vs PGE2 0.7811 (ns) 0.4621 (ns) 0.1999 (ns) 0.7544 (ns) 0.0531 (ns)
ns = non significant; * p < 0.05; ** p < 0.01; *** p < 0.001.
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conditions, physically associates and colocalizes with 
EGFR following PGE2 treatment (Figure 4C–4E). 
Moreover, Caveolin-1 knockdown affected PGE2-
mediated EGFR-STAT3 association, highlighting the 
functional role of Caveolin endocytosis in PGE2 activity. 
(Figure 4F–4G and Supplementary Figures 4 and 5).
By analyzing the expression of target genes of 
nuclear EGFR in NSCLC cells, we found that CCND1, 
PTGS2, MYC and NOS2 mRNA levels were upregulated 
by EGF as well as by PGE2, yet with different kinetics 
indicating the involvement of distinct internalization 
pathways (Figure 6 and Supplementary Figure 6). 
Interestingly, the combination of treatments induced a 
prolonged transcriptional activation of nuclear EGFR 
gene signature compared to individual stimuli (from 2-4 
to 8h), indicating that the PGE2 and EGF cooperate in their 
activities to sustain tumor progression. Additionally, by 
using cBioPortal for Cancer Genomics database, we have 
found a reduction in median months of survival in lung 
cancer patients that exhibit an upregulation of a nuclear 
EGFR gene signature, thus showing a trend between 
nuclear EGFR and poor prognosis in NSCLC (Figure 7). 
It is worth to mention that these data were derived from 
a non-selected patient population characterized by large 
differences in: age, sex, tumor stage, smoking history 
and therapy, therefore representing a heterogeneous 
situation. Among nuclear EGFR target genes, MYC is of 
high prognostic value in different epithelial tumors [43], 
and its expression is driven by PGE2 in NSLC cells [44]. 
Further, MYC appears to be one of the most amplified 
genes across nuclear EGFR transcriptional signature, 
further corroborating our findings.
Figure 9: Schematic model of nuclear EGFR signaling in NSCLC cells. The tumor microenvironment consists in cancer cells 
surrounded by different cell types such as stromal, endothelial, inflammatory and immune cells. In this scenario, single entities release 
mediators, cytokines and growth factors thereby supporting tumor progression. Particularly, EGF and PGE2 activate or transactivate EGFR 
leading to its internalization via dynamin-dependent Clathrin and Caveolin endocytosis. Further, Importin β1 transports the NLS-bearing 
EGFR across the nuclear envelope to the nucleoplasm. Within the nucleus, EGFR interacts with STAT3 or other transcription factors (TF) 
promoting the transcription of CCND1, PTGS2, MYC and NOS, a process that culminates with increased tumor cell proliferation.
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To demonstrate that tumor gene reprogramming 
promoted by EGF and PGE2-induced nuclear EGFR is 
critical for tumor progression, we have assessed cell 
proliferation by BrdU incorporation assay in NSCLC cells. 
A549 and GLC82 EGFR knockout cells expressing wild 
type EGFR increase in their proliferation in response to 
PGE2 or EGF in contrast to cells transfected with mutant 
EGFR into its nuclear localization sequence (Figure 
8B–8F and Supplementary Figure 7D-7H). Notably, the 
combined treatment potentiates nuclear EGFR mitogenic 
activity in terms of time and intensity, supporting the 
hypothesis of EGF and PGE2 malignant alliance.
In this scenario, we identified PGE2 as an inducer 
of EGFR nuclear translocation in NSCLC cells, an 
event, which has clinical correlate with poor prognosis 
[44, 45]. PGE2 coupling with EP receptor triggers EGFR 
internalization. In particular, we showed that EGFR 
undergoes to Clathrin- and Caveolin-mediated endocytosis 
leading to association with Importin β1 and consequent 
nuclear import. Within the nucleus, EGFR interacts with 
transcription factors such as STAT3 to regulate gene 
expression. Particularly, nuclear EGFR induced by EGF or 
PGE2 or the combination of treatments, promotes CCND1, 
PTGS2, MYC and NOS2 upregulation and sustains tumor 
growth (Figure 9), supporting the hypothesis that the gene 
signature associated with nuclear EGFR is correlated with 
poor prognosis in NSCLC and may serve as a biomarker for 
patients outcome and treatment selection.
Collectively, the findings of this work on EGFR 
nuclear import and gene transcription, assume the 
character of a self-feeding loop which leads to persistent 
up-regulation of CCND1, PTGS2, NOS2 and MYC, hence 
overproduction of PGE2, NO and overload of MYC which 
support a favorable pro-tumor microenvironment.
MATERIALS AND METHODS
Cell culture and cultured conditions
The human NSCLC cancer cell line A549 (CCL-
185), was purchased from American Type Culture 
Collection and the GLC82 NSCLC cell line was kindly 
provided by Dr. Mario Chiariello (Istituto Toscano 
Tumori, Siena, Italy). Cells were certified by STRA, 
(LGC Standards S.r.l., Sesto San Giovanni, Milan, Italy) 
and were cultured in DMEM for A549 and in RPMI-1640 
(Euroclone, Milan, Italy) for GLC82 supplemented with 
10% FBS and 2 mM Glutamine, 100 Units Penicillin and 
0.1mg/l Streptomycin (Sigma Aldrich, St. Louis, MO, 
USA) in a humidified incubator with 5% CO2 at 37°C. 
A549 and GLC82 were immediately expanded after 
delivery (up to 6 × 107 cells) and frozen down (1 × 106 
per vial) such that both cell lines could be restarted after 
a maximum of 10 passages every 3 months from a frozen 
vial of the same batch of cells. Control of mycoplasma 
was performed regularly using MycoAlert™ PLUS 
Mycoplasma Decection Kit (#LT07-710 Lonza, Basel, 
Switzerland).
Chemicals and reagents
Recombinant human EGF (#AF-100-15) was 
purchased from PeproTech (Rocky Hill, NJ, USA). PGE2 
(#P0409), Dynasore (#D7693), 5-N-Ethyl-N-isopropyl 
amiloride (EIPA) (#A3085) and Metil beta cyclodextrin 
(#C4555,) were purchased from Sigma Aldrich. 
Ruxolitinib (#S1378) was purchased from Selleckchem 
(Houston, TX, USA). STAT3 Inhibitor VII Calbiochem 
(#573103) was purchased from Merck Millipore 
(Darmstadt, Germany).
Antibodies
Anti-EGFR (#4267), anti-STAT3 (#9139), anti-
pSTAT3 Tyr 705 (#9138), anti-Caveolin-1 (#3267), 
anti-Clathrin Heavy Chain (#4796), anti-Importin-β1 
(#8673) antibodies were purchased from Cell Signaling 
Technology (Danvers, MA, USA). Anti-Tubulin antibody 
(#T9026) was purchased from Santa Cruz (Heidelberg, 
Germany). Anti-Lamin A (#SAB4501764), anti-Actin 
(#A5441) antibodies were obtained from Sigma Aldrich.
Whole cell extracts
Cells were washed 2x with cold Dulbecco’s 
Phosphate Buffered Saline (Sigma Aldrich) and lysed 
on ice with CelLytic™ MT Cell Lysis Reagent (#C3228 
Sigma Aldrich) supplemented with 2mM Na3VO4 and 1x 
Protease inhibitor cocktail for mammalian cells (#P2714 
Sigma Aldrich). Cell lysates were centrifuged at 16000 × g 
for 20 min at 4°C and the supernatants were then collected 
for immunoblot.
Cell fractionation
Nuclear and cytoplasmic extracts were prepared 
with NE-PER™ (#78833) nuclear and cytoplasmic 
extraction reagents (ThermoFisher Scientific, Waltham, 
MA, USA) following the manufacturer’s instructions as 
described previously [11].
Immunoblotting analysis
4 × 105 cells were plated in 60 mm dishes, serum 
deprived (0.1%. fetal calf serum, overnight), then treated 
as described in the text. Protein concentration was 
determined using the BCA protein assay kit (#23227 
ThermoFisher Scientific). For whole cell lysates, an equal 
amount of proteins were loaded on SDS–polyacrylamide 
gel and then transferred to a nitrocellulose membrane 
(#10600002 GE Healthcare Lifesciences) For cell 
fractionation experiments, 10μg of the cytosolic and 
40μg of the nuclear extracts were applied for SDS-
Oncotarget14955www.oncotarget.com
PAGE. Immunoblot analysis was performed as described 
previously [8, 10]. Signals were detected by SuperSignal 
WestPico Chemiluminescent Substrate (#34578 
ThermoFisher Scientific) using ChemiDoc system and 
Quantity one software (Bio-Rad, Hercules, CA, USA). 
All experiments were performed at least three times. For 
all experiments using whole cell lysate, Actin was used 
as loading control. Lamin-A and Tubulin were used as 
loading and purity controls for the nuclear and cytosolic 
fractions, respectively. Immunoblots were analyzed by 
densitometry using NIH Image J 1.48v software, and 
the results, expressed as arbitrary density units (A.D.U.) 
±SD, were normalized to Actin, EGFR, STAT3, Lamin-A 
or Tubulin.
Immunofluorescence microscopy analysis
Cells were plated on glass coverslips, starved 
overnight and treated as described in the text. Cells 
were fixed using 4% paraformaldehyde/PBS for 15 min 
and permeabilized with 0.5% NP-40 for 5 min. Next, 
cells were blocked using 3% BSA, 0.01% TritonX-100 
in PBS for 20 min. Furthermore, cells were incubated 
with anti-EGFR, overnight at 4°C followed by 3x 
washes with PBS/ 0.01% TritonX-100 and incubation 
with the AlexaFluor® 488-labeled (#A11034 Invitrogen, 
Carlsbad, CA, USA) for 60 min at room temperature. 
After 3x washes with PBS/ 0.01% TritonX-100, nuclei 
were stained with 6-diamidino-2- phenylindole (DAPI 
#D9542) or propidium iodide (PI #P4864) 1μg/ml (Sigma 
Aldrich) for 20 min. The coverslips were mounted with 
fluorescent mounting medium (#S3023 Dako, Glostrup, 
Denmark) on microscope slides. Cells were analyzed 
with a confocal laser scanning microscope Leica SP5. 
Images for documenting EGFR nuclear translocation 
and colocalization with Caveolin-1 were acquired in the 
middle section of the nuclei with 63x magnification.
Transfection of siRNAs and plasmids
siRNAs used for transient knock-down experiments 
were purchased from Qiagen (Hilden, Germany). Cells 
were transfected with 20nM targeting siRNA or scrambled 
control siRNA using Lipofectamine® RNAiMAX 
(#13778150 Invitrogen) according to manufacturer’s 
instructions. Cells were assayed 48-72h after transfection. 
Knockdown efficiency was assessed by immunoblotting. 
Target sequences are listed in Supplementary Table 3.
For DNA transfection, cells were transfected with 
1–10 μg plasmid using Lipofectamine® 2000 (#12566014 
Invitrogen) according to manufacturer’s instructions. 
EGFR WT and NLS mutant plasmids (NLSm12 and 
dNLS) were kindly provided by Prof. Mien-Chie Hung 
(University of Texas MD Anderson Cancer Center, 
Houston, TX, USA) [32]. pSpCas9(BB)-2A-GFP (PX458) 
(#48138) was purchased from Addgene. Cells were 
analyzed 24–96 h post-transfection.
Knockout of EGFR by CRISPR/Cas9-mediated 
genome editing
A549 and GLC82 EGFR knockout cells were 
generated by CRISPR/Cas9 as previously described [12].
Immunoprecipitation
1 × 106 were plated in 100 mm diameter dishes 
and starved overnight in 0.1% FBS. Then, cells were 
treated according to experimental design and lysed with 
CelLytic™ MT Cell Lysis Reagent (Sigma Aldrich) or 
subjected to cell fractionation with NE-PER™ nuclear 
and cytoplasmic extraction reagents (ThermoFisher 
Scientific). 300 μg of total proteins per sample were 
immunoprecipitated using Dynabeads™ Protein G 
Immunoprecipitation Kit (#10007D ThermoFisher 
Scientific) with an Anti-EGFR antibody (#4267 Cell 
signaling) following the manufacturer’s instructions. 
Immunoprecipitates were solubilized in LDS Sample 
Buffer (#NP0007 ThermoFisher Scientific) supplemented 
with Sample reducing agent (#NP0004 ThermoFisher 
Scientific), boiled for 10 min, separated in SDS/4-12% 
polyacrylamide gel and transferred onto nitrocellulose 
membranes. Immunoblotting analysis was performed 
using anti-STAT3 (#9139 Cell signaling) or anti-pSTAT3 
Tyr 705 (#9138 Cell signaling) antibodies.
Real time PCR
Total RNA was prepared using RNeasy Plus Kit 
(#74134 Qiagen) following manufacturer’s instructions. 1 
μg RNA was reverse transcribed using QuantiTect Reverse 
Transcription Kit (# 205313 Qiagen) and quantitative RT-
PCR was performed using QuantiNova SYBR Green PCR 
Kit (#208056 Qiagen) in a Rotor-Gene Q PCR machine 
(Qiagen). Fold change expression was determined by 
the comparative Ct method (ΔΔCt) normalized to 60S 
Ribosomal protein L19 expression. qRT-PCR data are 
represented as fold increase relative to non-treated 
cells (Control), which were assigned to 1. Primers for 
quantitative RT-PCR are listed in Supplementary Table 4.
Analysis of nuclear EGFR gene signature in 
TGCA provisional lung adenocarcinoma samples
cBioPortal for Cancer Genomics dataset (http://
cbioportal.org) was used to analyze the nuclear EGFR 
target gene signature, which consists of CCND1, 
PTGS2, MYC and NOS2 mRNA upregulation in 
lung adenocarcinoma TCGA study that includes 230 
sequenced samples [35, 36]. The summary of mRNA 
upregulation of nuclear EGFR target genes across 
tumor samples reported in the text was generated 
using OncoPrint view. The available survival data are 
displayed as Kaplan-Meier plots with P values derived 
from a logrank test.
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BrdU incorporation assay
Cell proliferation was determined by 5-bromo-
2′-deoxy-uridine (BrdU) incorporation using a 
chemioluminescence ELISA according to the 
manufacturer’s instructions (#11669915001 Roche 
Diagnostic S.p.A, Monza, Italy). Briefly, 3 × 103 cells were 
seeded in 96-well plate and starved overnight in growth 
medium 0.1% FBS. Next, cells were exposed to 5ng/ml 
EGF or 1μM PGE2 or combination of treatments for 8, 
16, 24, 36 and 48 h. BrdU was added during the late stage 
(8 h) of incubation. Then, cells were processed following 
manufacturer’s protocol. Chemiluminescence generated 
by BrdU labelled cells was measured using Infinite F200 
Pro luminometer (Tecan life sciences, Switzerland). Data 
are reported as % relative to non-treated cells.
Statistical analysis
Statistical analysis and graphs were generated using 
the GraphPad Prism software (San Diego, CA, USA). All 
statistical analysis was done by unpaired/paired Student’s 
t-test, p-value < 0.05 was considered significant.
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